Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

<i>ABL</i> Oncogenes and Phosphoinositide 3-Kinase: Mechanism of Activation and Downstream Effectors

15 Mar 2005

Abstract excerpt

The BCR-ABL oncogene is responsible for most cases of chronic myelogenous leukemia and some acute lymphoblastic leukemias. The fusion protein encoded by BCR-ABL possesses an aberrantly regulated tyrosine kinase activity. Imatinib mesylate (Gleevec, STI-571) is an inhibitor of ABL tyrosine kinase activity that has been remarkably effective in slowing disease progression in patients with chronic phase chronic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Myeloid Leukemia Treatments
Share to Eosinophilic Disorders and Syndromes
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 15781610
DOI: 10.1158/0008-5472.can-04-3888

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

<i>ABL</i> Oncogenes and Phosphoinositide 3-Kinase: Mechanism of Activation and Downstream EffectorsPMID 15781610Read ↗

A critical role for PLCG1 in RAS activation by BCR-ABL1 and FLT3-ITDSemantic proximity Read ↗

Targeting the mTOR Pathway in LeukemiaSemantic proximity Read ↗

Molecular biology of chronic myeloid leukemia.Semantic proximity Read ↗

Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.Semantic proximity Read ↗

The BCR-ABL Story: Bench to Bedside and BackSemantic proximity Read ↗

New Insights into the Pathophysiology of Chronic Myeloid Leukemia and Imatinib ResistanceSemantic proximity Read ↗

Targeting mutated protein tyrosine kinases and their signaling pathways in hematologic malignancies.Semantic proximity Read ↗

Signal transduction therapy in haematological malignancies: identification and targeting of tyrosine kinases.Semantic proximity Read ↗

BCR-ABL: The molecular mastermind behind chronic myeloid leukemiaSemantic proximity Read ↗

Molecular targets in acute myelogenous leukemia.Semantic proximity Read ↗

Oncogenic signaling: new insights and controversies from chronic myeloid leukemiaSemantic proximity Read ↗

Cell Cycle Regulation by Oncogenic Tyrosine Kinases in Myeloid Neoplasias: From Molecular Redox Mechanisms to Health ImplicationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.